Frameshift mutation in the APOA5 gene causing hypertriglyceridemia in a Pakistani family: Management and considerations for cardiovascular risk

Journal of Clinical Lipidology

Volumn 10, Issue 5, 2016, Pages 1272-1277

  Thériault, Sébastien ^a   Don Wauchope, Andrew ^a   Chong, Michael ^a   Lali, Ricky ^a   Morrison, Katherine M ^a   Paré, Guillaume ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

APOA5; Cardiovascular risk; Genetics; Hypertriglyceridemia; Management

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; ATENOLOL; BEZAFIBRATE; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; TRIACYLGLYCEROL; APOA5 PROTEIN, HUMAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOATING; BODY MASS; CARDIOVASCULAR RISK; CASE REPORT; CHILD; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 11; CONSANGUINITY; CORONARY ARTERY ANOMALY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE INCREASE; FAMILY HISTORY; FIRST-DEGREE RELATIVE; FRAMESHIFT MUTATION; GENE DELETION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HEART INFARCTION; HETEROZYGOTE; HOLTER MONITORING; HOMOZYGOTE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 5; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LEFT CORONARY ARTERY; LOW FAT DIET; MALE; MEDICATION COMPLIANCE; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAKISTANI; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RIGHT CORONARY ARTERY; SCHOOL CHILD; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; WHOLE EXOME SEQUENCING; XANTHOMA; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; GENETICS; PAKISTAN; PEDIGREE;

APOLIPOPROTEIN A-V; ASIAN CONTINENTAL ANCESTRY GROUP; BEZAFIBRATE; CHILD; DNA MUTATIONAL ANALYSIS; FRAMESHIFT MUTATION; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; PAKISTAN; PEDIGREE;

EID: 84994227029     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.07.009     Document Type: Article

References (25)

1. 1 Hegele, R.A., Ginsberg, H.N., Chapman, M.J., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2 (2014), 655–666.
2. 2 Pennacchio, L.A., Olivier, M., Hubacek, J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001), 169–173.
3. 3 Garelnabi, M., Lor, K., Jin, J., Chai, F., Santanam, N., The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research. Clin Biochem 46 (2013), 12–19.
4. 4 Charriere, S., Cugnet, C., Guitard, M., et al. Modulation of phenotypic expression of APOA5 Q97X and L242P mutations. Atherosclerosis 207 (2009), 150–156.
5. 5 Dorfmeister, B., Zeng, W.W., Dichlberger, A., et al. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol 28 (2008), 1866–1871.
6. 6 Dussaillant, C., Serrano, V., Maiz, A., et al. APOA5 Q97X mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a Chilean consanguineous family. BMC Med Genet, 13, 2012, 106.
7. 7 Evans, D., Aberle, J., Beil, F.U., Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia. Atherosclerosis 219 (2011), 715–720.
8. 8 Johansen, C.T., Wang, J., Lanktree, M.B., et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 42 (2010), 684–687.
9. 9 Marcais, C., Verges, B., Charriere, S., et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 115 (2005), 2862–2869.
10. 10 Mendoza-Barbera, E., Julve, J., Nilsson, S.K., et al. Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia. J Lipid Res 54 (2013), 649–661.
11. 11 Okubo, M., Ishihara, M., Iwasaki, T., et al. A novel APOA5 splicing mutation IVS2+1g>a in a Japanese chylomicronemia patient. Atherosclerosis 207 (2009), 24–25.
12. 12 Pisciotta, L., Fresa, R., Bellocchio, A., et al. Two novel rare variants of APOA5 gene found in subjects with severe hypertriglyceridemia. Clin Chim Acta 412 (2011), 2194–2198.
13. 13 Priore Oliva, C., Carubbi, F., Schaap, F.G., Bertolini, S., Calandra, S., Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J Intern Med 263 (2008), 450–458.
14. 14 Priore Oliva, C., Pisciotta, L., Li Volti, G., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25 (2005), 411–417.
15. 15 Priore Oliva, C., Tarugi, P., Calandra, S., et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis 188 (2006), 215–217.
16. 16 Elosua, R., Ordovas, J.M., Cupples, L.A., et al. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 47 (2006), 990–996.
17. 17 De Caterina, R., Talmud, P.J., Merlini, P.A., et al. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis 214 (2011), 397–403.
18. 18 Do, R., Stitziel, N.O., Won, H.H., et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518 (2015), 102–106.
19. 19 Nakano, Y., Shimizu, W., Genetics of long-QT syndrome. J Hum Genet 61 (2016), 51–55.
20. 20 Lookene, A., Beckstead, J.A., Nilsson, S., Olivecrona, G., Ryan, R.O., Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 280 (2005), 25383–25387.
21. 21 Sun, G., Bi, N., Li, G., et al. Identification of lipid binding and lipoprotein lipase activation domains of human apoAV. Chem Phys Lipids 143 (2006), 22–28.
22. 22 Gaudet, D., Alexander, V.J., Baker, B.F., et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med 373 (2015), 438–447.
23. 23 Gaudet, D., Brisson, D., Tremblay, K., et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371 (2014), 2200–2206.
24. 24 Baroukh, N., Bauge, E., Akiyama, J., et al. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 24 (2004), 1297–1302.
25. 25 Qamar, A., Khetarpal, S.A., Khera, A.V., Qasim, A., Rader, D.J., Reilly, M.P., Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol 35 (2015), 1880–1888.